{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:12:09Z","timestamp":1793052729249,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.numecd.2024.09.028","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T20:30:55Z","timestamp":1727469055000},"page":"103758","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Adverse event reporting of combining SGLT2 inhibitor and GLP1 receptor agonist: A real-world study from FAERS"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7759-5221","authenticated-orcid":false,"given":"Chunyan","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.numecd.2024.09.028_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2337\/ds19-0031","article-title":"Combining glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors to target multiple organ defects in type 2 diabetes","volume":"33","author":"Anderson","year":"2020","journal-title":"Diabetes Spectr"},{"issue":"12","key":"10.1016\/j.numecd.2024.09.028_bib2","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1172\/JCI97233","article-title":"Discovery, characterization, and clinical development of the glucagon-like peptides","volume":"127","author":"Drucker","year":"2017","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.numecd.2024.09.028_bib30","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/dom.12982","article-title":"Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor","volume":"19","author":"DeFronzo","year":"2017","journal-title":"Diabetes Obes Metabol"},{"issue":"1","key":"10.1016\/j.numecd.2024.09.028_bib19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12933-023-01798-4","article-title":"Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)","volume":"22","author":"Gourdy","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.numecd.2024.09.028_bib7","article-title":"The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.numecd.2024.09.028_bib3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/dom.12244","article-title":"Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes Obes Metabol"},{"issue":"22","key":"10.1016\/j.numecd.2024.09.028_bib4","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.numecd.2024.09.028_bib5","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.numecd.2024.09.028_bib6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jcjd.2020.09.005","article-title":"Practical considerations and rationale for glucagon-like peptide-1 receptor agonist plus sodium-dependent glucose cotransporter-2 inhibitor combination therapy in type 2 diabetes","volume":"45","author":"Goldenberg","year":"2021","journal-title":"Can J Diabetes"},{"issue":"11","key":"10.1016\/j.numecd.2024.09.028_bib8","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.numecd.2024.09.028_bib9","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00125-017-4301-8","article-title":"SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System","volume":"60","author":"Fadini","year":"2017","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.numecd.2024.09.028_bib10","article-title":"Frequency of urinary tract infections in type 2 diabetic patients taking dapagliflozin","volume":"14","author":"Khan","year":"2022","journal-title":"Cureus"},{"issue":"11","key":"10.1016\/j.numecd.2024.09.028_bib11","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/M19-0085","article-title":"Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases","volume":"170","author":"Bersoff-Matcha","year":"2019","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.numecd.2024.09.028_bib12","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/dom.12982","article-title":"Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor","volume":"19","author":"DeFronzo","year":"2017","journal-title":"Diabetes Obes Metabol"},{"issue":"5","key":"10.1016\/j.numecd.2024.09.028_bib13","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.numecd.2024.09.028_bib14","article-title":"GLP-1 receptor agonist-associated tumor adverse events: a real-world study from 2004 to 2021 based on FAERS","volume":"13","author":"Yang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.numecd.2024.09.028_bib31","doi-asserted-by":"crossref","DOI":"10.1186\/s43162-020-00026-9","article-title":"Mildly symptomatic liraglutide-induced acute pancreatitis in a patient with type 2 diabetes mellitus: a case report","volume":"32","author":"Gameil","year":"2020","journal-title":"Egypt J Intern Med."},{"issue":"12","key":"10.1016\/j.numecd.2024.09.028_bib32","article-title":"An atypical presentation of dulaglutide-induced pancreatitis complicated by superior mesenteric vein thrombosis","volume":"15","author":"Manuel","year":"2023","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.numecd.2024.09.028_bib33","article-title":"Pancreatitis in a 57-year-old female two weeks after initiation of empagliflozin","volume":"9","author":"Poloju","year":"2023","journal-title":"AACE Clin Case Rep"},{"issue":"10","key":"10.1016\/j.numecd.2024.09.028_bib15","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.2337\/dc19-1350","article-title":"Efficacy and safety over 2 Years of exenatide plus dapagliflozin in the DURATION-8 study: a multicenter, double-blind, phase 3, randomized controlled trial","volume":"43","author":"Jabbour","year":"2020","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.numecd.2024.09.028_bib17","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nbt.3623","article-title":"Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data","volume":"34","author":"Sarangdhar","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"6","key":"10.1016\/j.numecd.2024.09.028_bib18","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/14740338.2017.1325463","article-title":"Methods for safety signal detection in healthcare databases: a literature review","volume":"16","author":"Arnaud","year":"2017","journal-title":"Expet Opin Drug Saf"},{"issue":"12","key":"10.1016\/j.numecd.2024.09.028_bib20","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"Fr\u00edas","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.numecd.2024.09.028_bib21","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.cjca.2022.04.029","article-title":"Canadian cardiovascular society guideline for use of GLP-1 receptor agonists and SGLT2 inhibitors for cardiorenal risk reduction in adults","volume":"38","author":"Mancini","year":"2022","journal-title":"Can J Cardiol"},{"issue":"4","key":"10.1016\/j.numecd.2024.09.028_bib22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1590\/2175-8239-jbn-2020-0100","article-title":"Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection","volume":"42","author":"Sridhar","year":"2020","journal-title":"J Bras Nefrol"},{"key":"10.1016\/j.numecd.2024.09.028_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101213","article-title":"Association of glucagon-like peptide 1 analogs and agonists administered for obesity with weight loss and adverse events: a systematic review and network meta-analysis","volume":"42","author":"Vosoughi","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"8","key":"10.1016\/j.numecd.2024.09.028_bib27","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/CIRCULATIONAHA.120.047965","article-title":"Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy","volume":"143","author":"Dave","year":"2021","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.numecd.2024.09.028_bib24","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1111\/dom.14108","article-title":"Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: a systematic review and meta-analysis","volume":"22","author":"Mantsiou","year":"2020","journal-title":"Diabetes Obes Metabol"},{"issue":"1","key":"10.1016\/j.numecd.2024.09.028_bib25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-019-0942-x","article-title":"Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial","volume":"18","author":"Clegg","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.numecd.2024.09.028_bib26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/dom.14179","article-title":"Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: post hoc analyses from DECLARE-TIMI 58","volume":"23","author":"Cahn","year":"2021","journal-title":"Diabetes Obes Metabol"},{"issue":"4","key":"10.1016\/j.numecd.2024.09.028_bib28","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2337\/dc21-1113","article-title":"Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes","volume":"45","author":"Wright","year":"2022","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.numecd.2024.09.028_bib29","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2337\/dc19-2535","article-title":"Risk of major adverse cardiovascular events, severe hypoglycemia, and all-cause mortality for widely used antihyperglycemic dual and triple therapies for type 2 diabetes management: a cohort study of all Danish users","volume":"43","author":"Jensen","year":"2020","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.numecd.2024.09.028_bib16","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","article-title":"Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Ludvik","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.numecd.2024.09.028_bib34","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","article-title":"Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial","volume":"99","author":"Kraus","year":"2021","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.numecd.2024.09.028_bib35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/dme.12594","article-title":"Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment","volume":"32","author":"Von Scholten","year":"2015","journal-title":"Diabet Med"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475324003776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475324003776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T22:10:44Z","timestamp":1734041444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475324003776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0939475324003776"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2024.09.028","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse event reporting of combining SGLT2 inhibitor and GLP1 receptor agonist: A real-world study from FAERS","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2024.09.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103758"}}